收藏切换
Research progress of antibody-coupled drug-related interstitial lung disease
收藏切换
Zhangxiang JIAN1, Weiping ZHANG2, *
World Clinical Drug | 2026, 47(1) : 93 - 98
Less
收藏切换
World Clinical Drug | 2026, 47(1): 93-98
• Review •
Research progress of antibody-coupled drug-related interstitial lung disease
Full
Zhangxiang JIAN1, Weiping ZHANG2, *
Affiliations
  • 1.The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hanghzou 310053, Zhejiang Province, China
  • 2.Department of Oncology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hanghzou 310005, Zhejiang Province, China
Published: 2026-01-10 doi: 10.13683/j.wph.2026.01.014
Outline
收藏切换

As a cutting-edge and potential novle class of anti-tumor drug, antibody-drug conjugates(ADC)have shown significant efficacy in a variety of tumor treatments. However, with the widespread use of ADC, the related adverse reactions have attracted more and more attention. Interstitial lung disease(ILD) is a serious and life-threatening adverse reactions, which is usually characterized by progressive dyspnea, cough, chest pain, hypoxemia and low-grade fever. The mechanism of ADC-related ILD is complex, involving multi-dimensional factors, and due to the lack of specific diagnostic criteria of ILD, high vigilance must be maintained in clinical practice, problems should be identified early and timely intervention. This review aims to sort out the pathogenesis, diagnostic evaluation and management strategies of ADC-related ILD, helping clinicians understand and master the characteristics of pulmonary toxicity of ADC, so as to reduce and avoid serious adverse reactions and ensure the effectiveness and safety of ADC therapy in clinical application.

antibody-coupled drugs  /  interstitial lung disease  /  adverse drug events and management  /  pathogenesis
简张翔, 张卫平. 抗体偶联药物相关间质性肺病的研究进展. 世界临床药物, 2026 , 47 (1) : 93 -98 . DOI: 10.13683/j.wph.2026.01.014
Zhangxiang JIAN, Weiping ZHANG. Research progress of antibody-coupled drug-related interstitial lung disease[J]. World Clinical Drug, 2026 , 47 (1) : 93 -98 . DOI: 10.13683/j.wph.2026.01.014
Year 2026 volume 47 Issue 1
66
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.01.014
  • Receive Date:2025-06-23
  • Online Date:2026-11-05
  • Published:2026-01-10
Article Data
Affiliations
History
  • Received:2025-06-23
Funding
Affiliations
    1.The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hanghzou 310053, Zhejiang Province, China
    2.Department of Oncology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hanghzou 310005, Zhejiang Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.01.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT